Do Th17 Lymphocytes and IL-17 Contribute to Parkinson's Disease? A Systematic Review of Available Evidence
Parkinson's disease (PD) is a neurodegenerative disease characterized by progressive loss of dopaminergic neurons, appearance of Lewy bodies and presence of neuroinflammation. No treatments currently exist to prevent PD or delay its progression, and dopaminergic substitution treatments just rel...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-01-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fneur.2019.00013/full |
| _version_ | 1818944479511445504 |
|---|---|
| author | Elisa Storelli Niccolò Cassina Emanuela Rasini Franca Marino Marco Cosentino |
| author_facet | Elisa Storelli Niccolò Cassina Emanuela Rasini Franca Marino Marco Cosentino |
| author_sort | Elisa Storelli |
| collection | DOAJ |
| description | Parkinson's disease (PD) is a neurodegenerative disease characterized by progressive loss of dopaminergic neurons, appearance of Lewy bodies and presence of neuroinflammation. No treatments currently exist to prevent PD or delay its progression, and dopaminergic substitution treatments just relieve the consequences of dopaminergic neuron loss. Increasing evidence points to peripheral T lymphocytes as key players in PD, and recently there has been growing interest into the specific role of T helper (Th) 17 lymphocytes. Th17 are a proinflammatory CD4+ T cell lineage named after interleukin (IL)-17, the main cytokine produced by these cells. Th17 are involved in immune-related disease such as psoriasis, rheumatoid arthritis and inflammatory bowel disease, and drugs targeting Th17/IL-17 are currently approved for clinical use in such disease. In the present paper, we first summarized current knowledge about contribution of the peripheral immune system in PD, as well as about the physiopharmacology of Th17 and IL-17 together with its therapeutic relevance. Thereafter, we systematically retrieved and evaluated published evidence about Th17 and IL-17 in PD, to help assessing Th17/IL-17-targeting drugs as potentially novel antiparkinson agents. Critical appraisal of the evidence did not allow to reach definite conclusions: both animal as well as clinical studies are limited, just a few provide mechanistic evidence and none of them investigates the eventual relationship between Th17/IL-17 and clinically relevant endpoints such as disease progression, disability scores, intensity of dopaminergic substitution treatment. Careful assessment of Th17 in PD is anyway a priority, as Th17/IL-17-targeting therapeutics might represent a straightforward opportunity for the unmet needs of PD patients. |
| first_indexed | 2024-12-20T07:43:53Z |
| format | Article |
| id | doaj.art-e95b20dfb4d74338986e674b3eb016c7 |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-12-20T07:43:53Z |
| publishDate | 2019-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-e95b20dfb4d74338986e674b3eb016c72022-12-21T19:48:02ZengFrontiers Media S.A.Frontiers in Neurology1664-22952019-01-011010.3389/fneur.2019.00013426072Do Th17 Lymphocytes and IL-17 Contribute to Parkinson's Disease? A Systematic Review of Available EvidenceElisa StorelliNiccolò CassinaEmanuela RasiniFranca MarinoMarco CosentinoParkinson's disease (PD) is a neurodegenerative disease characterized by progressive loss of dopaminergic neurons, appearance of Lewy bodies and presence of neuroinflammation. No treatments currently exist to prevent PD or delay its progression, and dopaminergic substitution treatments just relieve the consequences of dopaminergic neuron loss. Increasing evidence points to peripheral T lymphocytes as key players in PD, and recently there has been growing interest into the specific role of T helper (Th) 17 lymphocytes. Th17 are a proinflammatory CD4+ T cell lineage named after interleukin (IL)-17, the main cytokine produced by these cells. Th17 are involved in immune-related disease such as psoriasis, rheumatoid arthritis and inflammatory bowel disease, and drugs targeting Th17/IL-17 are currently approved for clinical use in such disease. In the present paper, we first summarized current knowledge about contribution of the peripheral immune system in PD, as well as about the physiopharmacology of Th17 and IL-17 together with its therapeutic relevance. Thereafter, we systematically retrieved and evaluated published evidence about Th17 and IL-17 in PD, to help assessing Th17/IL-17-targeting drugs as potentially novel antiparkinson agents. Critical appraisal of the evidence did not allow to reach definite conclusions: both animal as well as clinical studies are limited, just a few provide mechanistic evidence and none of them investigates the eventual relationship between Th17/IL-17 and clinically relevant endpoints such as disease progression, disability scores, intensity of dopaminergic substitution treatment. Careful assessment of Th17 in PD is anyway a priority, as Th17/IL-17-targeting therapeutics might represent a straightforward opportunity for the unmet needs of PD patients.https://www.frontiersin.org/article/10.3389/fneur.2019.00013/fullParkinson's diseaseTh17 lymphocytesinterleukin-17neuroinflammationneurodegenerationperipheral immunity |
| spellingShingle | Elisa Storelli Niccolò Cassina Emanuela Rasini Franca Marino Marco Cosentino Do Th17 Lymphocytes and IL-17 Contribute to Parkinson's Disease? A Systematic Review of Available Evidence Frontiers in Neurology Parkinson's disease Th17 lymphocytes interleukin-17 neuroinflammation neurodegeneration peripheral immunity |
| title | Do Th17 Lymphocytes and IL-17 Contribute to Parkinson's Disease? A Systematic Review of Available Evidence |
| title_full | Do Th17 Lymphocytes and IL-17 Contribute to Parkinson's Disease? A Systematic Review of Available Evidence |
| title_fullStr | Do Th17 Lymphocytes and IL-17 Contribute to Parkinson's Disease? A Systematic Review of Available Evidence |
| title_full_unstemmed | Do Th17 Lymphocytes and IL-17 Contribute to Parkinson's Disease? A Systematic Review of Available Evidence |
| title_short | Do Th17 Lymphocytes and IL-17 Contribute to Parkinson's Disease? A Systematic Review of Available Evidence |
| title_sort | do th17 lymphocytes and il 17 contribute to parkinson s disease a systematic review of available evidence |
| topic | Parkinson's disease Th17 lymphocytes interleukin-17 neuroinflammation neurodegeneration peripheral immunity |
| url | https://www.frontiersin.org/article/10.3389/fneur.2019.00013/full |
| work_keys_str_mv | AT elisastorelli doth17lymphocytesandil17contributetoparkinsonsdiseaseasystematicreviewofavailableevidence AT niccolocassina doth17lymphocytesandil17contributetoparkinsonsdiseaseasystematicreviewofavailableevidence AT emanuelarasini doth17lymphocytesandil17contributetoparkinsonsdiseaseasystematicreviewofavailableevidence AT francamarino doth17lymphocytesandil17contributetoparkinsonsdiseaseasystematicreviewofavailableevidence AT marcocosentino doth17lymphocytesandil17contributetoparkinsonsdiseaseasystematicreviewofavailableevidence |